Article date: 1992/9/1
PubMed ID: 1480515
Journal name: Peptides (ISSN: 0196-9781)
Dopamine and gamma-aminobutyric acid (GABA) inhibit POMC peptide release from the pituitary intermediate lobe, via interaction with D2 or GABA-A/benzodiazepine receptors. Here, we examined the effects of an antianxiety triazolobenzodiazepine, adinazolam, on corticotropin-releasing factor (CRF)-stimulated POMC peptide secretion from the rat neurointermediate pituitary. Neurointermediate lobes (NILS) were incubated with CRF (10(-7) M), then adinazolam (10(-8) or (10(-9) M) was added, with CRF remaining in the medium. Aliquots were removed at 15-min intervals and frozen for radioimmunoassay of beta-endorphin. Adinazolam alone did not significantly affect secretion as compared to controls or CRF alone. Adinazolam incubated with CRF led to significant inhibition of beta-endorphin secretion, as compared to CRF alone. In addition, adinazolam was as effective as dopamine or the CRF antagonist, alpha-helical CRF, in preventing CRF-induced beta-endorphin release. Adinazolam appears to act directly on the pituitary to suppress hormone release induced by a stress-related hypothalamic peptide.
Author List: Saland L C, Carr J A, Samora A, Tejeda D
Publication Types: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
Substances mentioned in the article: Anti-Anxiety Agents; Benzodiazepines; Muscimol; beta-Endorphin; Corticotropin-Releasing Hormone; Baclofen; adinazolam; Dopamine;
Mesh terms: Animals; Anti-Anxiety Agents; Baclofen/pharmacology; Benzodiazepines/pharmacology; Corticotropin-Releasing Hormone/antagonists & inhibitors; Dopamine/pharmacology; In Vitro Techniques; Male; Muscimol/pharmacology; Pituitary Gland/drug effects; Rats; Rats, Sprague-Dawley; beta-Endorphin/secretion;